Physician profile
Charles E Dugan
NPI 1215478649
$722.87
in general payments reported to CMS, 2019-2025
16 companies · $80.30 in 2025
The $80.30 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.84 · 2022: $227 · 2023: $116 · 2024: $276 · 2025: $80.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $226.49 | 2022-2023 | Nuzyra |
| Biogen, INC. | $87.50 | 2022 | |
| Amgen INC. | $68.19 | 2024 | Prolia, Evenity |
| Lilly USA, LLC | $61.71 | 2022-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $40.87 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $29.32 | 2024 | Airsupra |
| Irhythm Technologies, INC. | $27.45 | 2024 | Zio Xt Patch, Zio Monitor |
| Abiomed | $26.67 | 2024 | Impella |
| Baxter Healthcare | $25.53 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $22.84 | 2021 | |
| Pfizer INC. | $22.16 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.06 | 2024 | Rexulti |
| Astellas Pharma US INC | $18.13 | 2024 | Veozah |
| Exact Sciences Corporation | $17.27 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.66 | 2024 | Trintellix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.